The drug, known generically as exagamglogene autotemcel, targets sickle cell disease patients suffering from recurrent vaso-occlusive crises, alongside individuals with transfusion-dependent β-thalassemia. By lowering the age threshold, regulators aim to broaden the reach of a therapy that fundamentally alters the genetic basis of these blood disorders.

This approval represents the eighth selection for the FDA Commission’s National Priority Voucher pilot program. While the therapy was already established for adolescents and adults, the inclusion of younger children signals a significant shift in the clinical management of severe blood conditions, moving intervention earlier in the patient’s life cycle.